Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 12/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.39 |
| ▸ | RHEB | Q15382 | 2/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6000223 | 0.84 | SLC6A4 (0.57) | HTR2ASLC6A4KCNH2SLC6A2SLC6A3 | |
| SCHEMBL5497887 | 0.81 | RHEB (0.51) | HTR2ASLC6A4KCNH2RHEBTRPM8 | |
| SCHEMBL5998869 | 0.80 | ADRB2 (0.39) | HTR2ASLC6A4KCNH2TRPM8SLC6A2 | |
| SCHEMBL6000269 | 0.79 | SLC6A4 (0.39) | HTR2ASLC6A4KCNH2RHEBTRPM8 | |
| SCHEMBL5999629 | 0.78 | SLC6A4 (0.37) | HTR2ASLC6A4KCNH2SLC6A2SLC6A3 | |
| SCHEMBL5502216 | 0.77 | SLC6A4 (0.42) | HTR2ASLC6A4KCNH2TRPM8SLC6A2 | |
| SCHEMBL6000215 | 0.74 | RHEB (0.46) | HTR2ASLC6A4KCNH2RHEBTRPM8 | |
| SCHEMBL5503983 | 0.73 | SLC6A4 (0.50) | HTR2ASLC6A4KCNH2TRPM8SLC6A2 | |
| SCHEMBL6000147 | 0.71 | HTR2A (0.43) | HTR2ASLC6A4KCNH2TAAR1ADRA1A | |
| SCHEMBL6000287 | 0.69 | RHEB (0.66) | HTR2ASLC6A4KCNH2RHEBTRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | HTR2A 7/4885SLC6A4 150/4885KCNH2 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.